APOA2 (Gene)

Organism:

Homo sapiens

Taxonomy (Entity type)

Synonyms:APOA2, Apo-AII, ApoA-II, ENTREZ:336, HGNC:601, MIM:107670, NM_001643, NP_001634, apoAII, apolipoprotein A2

Omim:OMIM:107670

Nci:C189197

Id:ENSG00000158874

Hgnc:HGNC:601

Entrez:336

Ensembl:ENSG00000158874

Description:apolipoprotein A2

This gene encodes apolipoprotein (apo-) A-II, which is the second most abundant protein of the high density lipoprotein particles. The protein is found in plasma as a monomer, homodimer, or heterodimer with apolipoprotein D. Defects in this gene may result in apolipoprotein A-II deficiency or hypercholesterolemia. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View APOA2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with APOA2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using APOA2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for APOA2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with APOA2.

Results found

Linked to

	Label	Description
	GSE195559 NOTCH1 knockout endothelial cell cardiac muscle cell stem cell 2 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228430 FABP5 inhibition Huh-7 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE210655 3 V 2 CISPLATIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE220520 3 V 4 ETHANOL MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE198930 prunetin AGS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158458 2 V 1 SORAFENIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE152441,GSE152442 6 V 5 FOLIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE168745 H-7 JHH-7 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE109140 2 V 3 VALPROIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE195559 NOTCH1 knockout endothelial cell cardiac muscle cell stem cell 2 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE228430 FABP5 inhibition Huh-7 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE210655 3 V 2 CISPLATIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE220520 3 V 4 ETHANOL MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE198930 prunetin AGS 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158458 2 V 1 SORAFENIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE152441,GSE152442 6 V 5 FOLIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE168745 H-7 JHH-7 0 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE109140 2 V 3 VALPROIC ACID HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.